Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its price target raised by analysts at JMP Securities from $42.00 to $45.00. They now have a "market outperform" rating on the stock.
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event [Yahoo! Finance]
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event